February 07, 2026 11:39 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Namaste Trump beat Howdy Modi’: Congress slams PM Over India-US trade deal | Historic India-US trade pact: Tariffs cut, $500B market opportunity unlocked! | Big call from RBI: Repo rate stays at 5.25%, neutral stance continues | RG Kar scam twist: Court issues non-bailable warrant against whistle-blower Akhtar Ali | Court snub for Vijay: Madras HC rejects plea in ₹1.5 crore tax case | ‘We never said no’: Suryakumar Yadav says India ready for Pakistan clash at T20 World Cup | Supreme Court orders Mamata govt to clear pending dues | ‘India is free to buy oil from anyone’: Russia fires back at Trump’s crude deal claim | ‘Justice crying behind closed doors’: Mamata Banerjee slams ECI in Supreme Court, CJI Kant assures solution | Mummy, Papa, sorry: Three sisters jump to death after parents object to online gaming
Sinopharm
WIKIMEDIA COMMONS

China's Sinopharm COVID-19 vaccine safe and efficacious: WHO official

| @indiablooms | May 12, 2021, at 06:28 pm

Geneva/UNI: China's Sinopharm COVID-19 vaccines, very much used globally, have been considered both safe and efficacious, according to Mariangela Simao, World Health Organization (WHO) assistant director general for access to health products.

"We still have data proving that they are efficacious against severe disease," she said in a press conference on Monday. "Sinopharm has been very much used globally. I think 62 million doses have already been applied. It has been considered both safe and efficacious."

WHO Director-General Tedros Adhanom Ghebreyesus announced last week that China's Sinopharm COVID-19 vaccine has been validated for emergency use, marking the first Chinese vaccine officially recognized by the WHO.

The approval came after an extensive review by an external, technical advisor group that looked at different data, Simao added.

"We did site inspections in China in January and February... We accessed the clinical data available for Sinopharm. It was also considered suitable, and (with) efficacy and safety in good manufacturing practice," she noted.

She also mentioned that the WHO is committed to the COVAX Facility, which is "an equitable access mechanism that we are very much working on and striving to get enough doses to be distributed."

The official called for a change in the code of behavior, as many vaccine producers "are moving towards a profit-driven approach instead of an equitable-access approach."

"So (the) WHO is pushing very hard at the highest level for everyone who is manufacturing vaccines to consider putting those vaccines in a global mechanism that will ensure that all countries have access to them, not only high-income countries who can pay more for the vaccines, as we are seeing as we speak right now," Simao said.

"The code of behavior, when you talk about it, is not for vaccine nationalism. It is for everyone who has a product that can be a public health good and can help us in this acute phase of this pandemic," she stressed.

 

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.